Sunshine Biopharma wins Canadian approval for generic Enalapril tablets

• Sunshine Biopharma won Canadian regulatory clearance for generic Enalapril tablets, expanding its cardiovascular portfolio.
• Shipments to Canadian pharmacies targeted by end-2026 via subsidiary Nora Pharma’s distribution network.
• Move positions the company for demand in the global anti-hypertensive market, valued at USD 25.94 billion in 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sunshine Biopharma Inc. published the original content used to generate this news brief on August 19, 2026, and is solely responsible for the information contained therein.